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Abstract The in vivo roles for even the most intensely studied microRNAs remain poorly
defined. Here, analysis of mouse models revealed that let-7, a large and ancient microRNA family,
performs tumor suppressive roles at the expense of regeneration. Too little or too much let-7
resulted in compromised protection against cancer or tissue damage, respectively. Modest let-7
overexpression abrogated MYC-driven liver cancer by antagonizing multiple let-7 sensitive
oncogenes. However, the same level of overexpression blocked liver regeneration, while let-7
deletion enhanced it, demonstrating that distinct let-7 levels can mediate desirable phenotypes.
let-7 dependent regeneration phenotypes resulted from influences on the insulin-PI3K-mTOR
pathway. We found that chronic high-dose let-7 overexpression caused liver damage and
degeneration, paradoxically leading to tumorigenesis. These dose-dependent roles for let-7 in
tissue repair and tumorigenesis rationalize the tight regulation of this microRNA in development,
and have important implications for let-7 based therapeutics.
DOI: 10.7554/eLife.09431.001
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Introduction
MicroRNAs are thought to control cellular responses to stresses such as tissue damage and transfor-
mation (Leung and Sharp, 2010; Chivukula et al., 2014), but the impact of this idea is unclear
because microRNAs have been understudied in vivo. let-7 is one of the most ancient and omnipres-
ent microRNAs, yet relatively little is known about its functional roles in mammalian development
and physiology. let-7 was first identified as a gene that regulates the timing of developmental mile-
stones in a C. elegans screen (Reinhart et al., 2000). In mammals, mature let-7 is undetectable in
early embryos and embryonic stem cells, but becomes highly expressed in most adult tissues
(Schulman et al., 2005; Thomson et al., 2006). A handful of previous studies have implicated let-7
in body size regulation, metabolism, stem cell self-renewal, and colon carcinogenesis (Zhu et al.,
2011; Frost and Olson, 2011; Shyh-Chang, et al., 2013; Nishino et al., 2013; Madison, et al.,
2013, but the core functions of let-7 in regeneration and disease remain incompletely understood.
In addition to questions about what let-7 does, it is unknown why so many let-7s are expressed at
such high levels. In mice and humans, the let-7 family is comprised of 10 to 12 members who are
thought to share a common set of mRNA targets. It has been thought that deep redundancy might
make it difficult to discern any phenotypes that individual let-7s might have. Essential unanswered
questions regarding let-7 biology include whether let-7 members are redundant, have unique func-
tions, or are regulated to maintain a specific total dose. Our previous study of Lin28a, which inhibits
the biogenesis of each let-7 member similarly (Heo et al., 2008; Nam et al., 2011), suggests that
total let-7 dose alterations, rather than regulation of specific members, is important. In transgenic
eLife digest The development of animals is guided by the expression of certain genes at critical
moments. Many different mechanisms control development; in one of them, the expression of genes
can be decreased by molecules called microRNAs. In particular, the group of microRNAs called let-7
has been intensively studied in roundworms and fruit flies. Although mammals have extremely
similar let-7 microRNAs they seem to be more important during adulthood.
Previous studies using cells grown in the laboratory have shown that mammalian let-7 microRNAs
decrease cell proliferation and cell growth. Furthermore, in mouse models of various cancers, let-7
microRNAs often reduce tumour growth when they are supplied to adult mice. Therefore, overall
the let-7 group has been classified as genes that act to suppress tumors, and thus protect mice (and
most likely humans too) from cancers. However, in-depth analysis of let-7 microRNAs was still
missing.
Wu and Nguyen et al. have now studied mice with liver cancer using strains where they were able
to regulate the levels of let-7. These mice overproduce a strong cancer-inducing gene in the liver;
half were used as controls and the other half were further engineered to have moderately elevated
levels of let-7 expression. Most of the control mice got large cancerous tumors, but only a few mice
in the other group developed cancers and the tumors were smaller. This confirmed that let-7 hinders
tumor formation.
Wu and Nguyen et al. also observed that the protected mice were less able to regenerate their
liver tissues. Further experiments showed that deleting just two out of ten let-7 microRNAs
enhanced the mice’s ability to regenerate liver tissue after injury. These findings indicate that let-7
microRNAs slow down the growth of both cancerous and normal cells. Lastly, when let-7 levels were
raised to very high levels for a prolonged amount of time this actually led to liver damage and
subsequent tumor formation.
This last observation may have important consequences for possible cancer therapies. Some
scientists have shown that providing extra let-7 can slow or even reverse tumour growth, but the
findings here clearly point out that too much let-7 could actually worsen the situation. Since the let-7
family comprises a handful of microRNAs in mammals, in the future it will also be important to find
out to what extent these molecules play overlapping roles and how much they differ.
DOI: 10.7554/eLife.09431.002
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mice, modest increase in Lin28a and consequent 40% suppression of total let-7 levels promote
increased glucose uptake and an overgrowth syndrome (Zhu et al., 2010).
In this study we examined the consequences of let-7 dose disruption in cancer and organ regen-
eration in genetic mouse models. While let-7s have been implicated as a tumor suppressor, this has
predominantly been shown in cell lines and xenograft assays (Guo et al., 2006; Chang et al., 2009;
Iliopoulos et al., 2009; Viswanathan et al., 2009; Wang et al., 2010; Lan et al., 2011), as well as
using exogenous let-7 delivery to mouse cancer models (Esquela-Kerscher et al., 2008;
Trang et al., 2010; Trang et al., 2011). Here, we confirmed the tumor suppressor activity of an
endogenous transgenic let-7 in a MYC-driven hepatoblastoma model. However, we found that this
same level of let-7 overexpression impaired liver regeneration after partial hepatectomy (PHx). Fur-
thermore, chronic high-dose let-7 resulted in severe liver damage and paradoxical liver cancer devel-
opment. Overall, we provide in vivo evidence that let-7 expression levels have been
developmentally constrained to balance the need for regenerative proliferation against the need to
antagonize malignant proliferation, findings with implications for let-7 based therapies.
Results
let-7g inhibits the development of MYC-driven hepatoblastoma
To study the effect of let-7 on carcinogenesis, we employed an inducible MYC-driven hepatoblas-
toma model (Shachaf et al., 2004). In this model, most let-7s are suppressed by more than 60%
(Nguyen et al., 2014). However, MYC affects the expression of many other microRNAs
(Chang et al., 2009; Kota et al., 2009). To test if let-7 suppression is specifically required for MYC’s
oncogenic program, we simultaneously overexpressed let-7g and MYC using a triple transgenic,
liver-specific, tet-off model (Figure 1A: LAP-tTA; TRE-MYC; TRE-let-7S21L transgenic mice). This
transgenic form of let-7g is an engineered let-7 species called let-7S21L (let-7g Stem + miR-21 Loop)
(Zhu et al., 2011), in which the precursor microRNA loop derives from mir-21 and cannot be bound
and inhibited by Lin28b (Figure 1B), which is highly expressed in MYC-driven tumors (Chang et al.,
2009; Nguyen et al., 2014).
Induction of MYC with or without let-7S21L was initiated at 14 days of age (Figure 1C). By 90
days of age, large multifocal tumors had formed in 88% of the MYC alone group, whereas single
small tumors appeared in only 27% the MYC + let-7S21L group (Figure 1D–F) and overall survival
was dramatically improved (Figure 1G). The level of let-7g was increased more than eightfold in
both non-tumor and tumor tissues (Figure 1H). Tumors from both groups showed similar histology
(Figure 1—figure supplement 1) and MYC expression (Figure 1I). Gene-expression within tumors
showed that previously validated let-7 targets involved in proliferation and growth including Cdc25a
(Johnson et al., 2007), Cdc34 (Legesse-Miller et al., 2009), E2f2 (Dong et al., 2010), E2f5
(Kropp et al., 2015), and Map4k4 (Tan et al., 2015) were upregulated in MYC-tumors, but sup-
pressed back down to normal levels in the context of let-7 overexpression (Figure 1J–L), suggesting
that the repression of these targets restrains MYC-dependent tumorigenesis. These data indicated
that let-7g has potent tumor suppressor activity in the context of MYC-driven hepatoblastoma.
let-7g overexpression inhibits liver regeneration after partial
hepatectomy
Since increasing let-7g was extremely effective at suppressing hepatoblastoma without compromis-
ing overall health, we asked if this increase in levels would impact tissue homestasis. We examined
let-7g overexpression in the setting of liver injuries that drive rapid proliferation and growth. After
PHx, let-7s in regenerating tissues fell, but returned to normal after forty hours (Figure 2A), findings
consistent with a previous report (Chen et al., 2011). Similarly, let-7s also declined acutely after
chemical injury with the xenobiotic TCPOBOP (1,4-bis-[2-[3,5-dichloropyridyloxy]] benzene) (Fig-
ure 2—figure supplement 1A). This shows that while let-7 increases in a temporally defined fashion
during development (Figure 2—figure supplement 1B), it can transiently fluctuate after environ-
mental perturbations. To test if the observed let-7 suppression is necessary for regeneration, we
induced let-7g in LAP-let-7S21L mice and performed PHx (Figure 2B–D). The body weight (Fig-
ure 2—figure supplement 1C), liver function (Figure 2—figure supplement 1D), resected liver
mass (Figure 2E) and histology (Figure 2—figure supplement 1E) were unaffected in LAP-let-7S21L
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mice compared to control mice. Forty hours after PHx, there was reduced liver mass and decreased
Ki-67 in LAP-let-7S21L mice (Figure 2F–H). Liver mass was no different at four and fourteen days,
indicating a kinetic delay but not a permanent impairment (Figure 2—figure supplement 1F,G).
To rule out increasing demands on microRNA biogenesis machinery as a mechanism of prolifer-
ative suppression, we delivered mature control or let-7g microRNA mimics (0.5 mg/kg) into wild-
type mice two days prior to hepatectomy using C12-200 lipidoid nanoparticles (LNPs) (Love et al.,
2010). let-7g, but not control mimics, inhibited regeneration (Figure 2I–K). While let-7
Figure 1. let-7g inhibits the development of MYC-driven hepatoblastoma. (A) Schema of the liver-specific inducible LAP-MYC +/- let-7S21L cancer
model. (B) let-7S21L is a chimeric construct containing the let-7g stem, miR-21 loop, and let-7g flanking sequences. (C) Schema showing that LAP-MYC
+/- let-7S21L mice were induced at 14 days of age, tissues were collected at 90 days of age, and survival was followed. (D) Ninety-day old mice bearing
tumors in the LAP-MYC (87.5%, 7/8) and LAP-MYC + let-7S21L (27.3%, 3/11) mouse models. (E) Livers showing tumors from the above mice. (F) Liver
surface area occupied by tumor. (G) Kaplan-Meier curve of LAP-MYC alone and LAP-MYC + let-7S21L mice. (H) Mature let-7 expression levels in as
determined by RT-qPCR. (I) Human c-MYC mRNA expressionin tumors as determined by RT-qPCR. (J) Heat map of let-7 target gene expression in WT
normal livers, MYC tumors, and MYC + let-7S21L tumors as measured by RT-qPCR. Red is higher and blue is lower relative mRNA expression. (K) Gene
expression plotted as bar graphs to show relative changes. (L) Evolutionarily conserved let-7 target sites within 3’UTRs (Targetscan.org). All data in this
figure are represented as mean ± SEM. *p < 0.05, **p < 0.01.
DOI: 10.7554/eLife.09431.003
The following figure supplement is available for figure 1:
Figure supplement 1. H&E staining of LAP-MYC and LAP-MYC + let-7S21L tumor-adjacent normal tissues and tumor tissues.
DOI: 10.7554/eLife.09431.004
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overexpression blocked MYC-induced tumorigenesis, these data show that a similar increase in let-7
levels inhibited post-injury organ growth and regeneration.
Figure 2. let-7g overexpression inhibits liver regeneration after partial hepatectomy. (A) Mature endogenous let-7 expression levels in WT C57Bl/6 mice
at different time points after PHx as determined by RT-qPCR (n=4 and 4 for each time point). (B) Schema of the LAP-let-7S21L dox-inducible model.
LAP-tTA single transgenic mice served as the controls. (C) Schema showing that let-7S21L control and LAP-let-7S21L mice were induced at 42 days
of age, PHx was performed after 14 days of induction, and tissues were collected 40 hr post PHx. (D) Mature let-7 expression levels in let-7S21L and
LAP-let-7S21L livers after 14 days of induction (n=4 and 4). (E) Resected liver/body weight ratios of LAP-tTA Control and LAP-let-7S21L mice at the time
of PHx (n=4 and 4). (F) Liver/body weight ratios 40 hr after PHx (n=4 and 4). (G) Ki-67 staining on resected and post-PHx liver tissues. (H) Quantification
of Ki-67-positive cells (n=2 and 2 mice; ten 20x fields for each mouse were quantified). (I) Resected liver/body weight ratios 2 days after intravenous
injection of 0.5 mg/kg negative control or let-7g microRNA mimics packaged in C12-200 LNPs (n=5 and 5). (J) Liver/body weight ratios 40 hr after PHx
(n=4 and 4). (K) Mature let-7g expression levels in mimic treated livers (n=5 and 5). All data in this figure are represented as mean ± SEM. *p<0.05,
**p<0.01.
DOI: 10.7554/eLife.09431.005
The following figure supplement is available for figure 2:
Figure supplement 1. Data associated with Figure 2.
DOI: 10.7554/eLife.09431.006
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Loss of let-7b and let-7c2 is sufficient to enhance liver regeneration
To assess the physiological relevance of our gain-of-function experiments, we examined knockout
mice to determine if let-7 is a bona fide regeneration suppressor. Both let-7b and let-7c2 were con-
ditionally deleted from the liver by crossing Albumin-Cre into a let-7b/c2 floxed mouse ("let-7b/c2
LKO" mice, Figure 3A). Small RNA-sequencing data from Xie et al. showed that let-7 is one of the
most highly expressed microRNA families in the liver and that let-7b and let-7c2 together comprise
approximately 18% of the let-7 total (Figure 3B) (Xie et al., 2012). Thus, let-7b/c2 LKO mice have
substantial, but far from a complete reduction of total let-7 levels.
These LKO mice were healthy and showed normal liver/body weight ratios and histology at base-
line (Figure 3—figure supplement 1A,B). An identical amount of liver mass was resected from let-
7b/c2Fl/Fl control and let-7b/c2 LKO mice (Figure 3C,D), but LKO mice exhibited significant
increases in liver mass and proliferation 40 hr after surgery (Figure 3E–G). Four and seven days after
PHx, there were no differences in liver weights, indicating that other phases of regeneration were
unaffected (Figure 3—figure supplement 1C,D). At fourteen days, the liver weight precisely
achieved pre-surgery levels in control and LKO mice, indicating accelerated but not excessive regen-
eration (Figure 3—figure supplement 1C,D). There was no compensatory upregulation of other let-
7s in pre- or post-PHx tissues (Figure 3H), supporting the concept that let-7 is a dose-dependent
regeneration suppressor.
Cre under the Albumin promoter is expressed in embryonic hepatoblasts that give rise to both
hepatocyte and bile duct compartments (Postic and Magnuson, 1999, 2000; Xu et al., 2006;
Weisend et al., 2009; Malato et al., 2011), so developmental influences of let-7 loss could have led
to adult phenotypes. To define cell- and temporal-specific roles of let-7b/c2, we used adeno-associ-
ated virus expressing Cre (AAV8.TBG.PI.Cre.rBG, hereafter called "AAV-Cre"), known to mediate
efficient gene excision in hepatocytes but never in biliary epithelial cells (Yanger et al., 2013) (Fig-
ure 3—figure supplement 2A,B). These adult and hepatocyte-specific conditional knockout mice
also exhibited significantly enhanced regenerative capacity (Figure 3—figure supplement 2C–F). To
test if proliferative effects are specific to particular let-7 species, we knocked-down either let-7a or
let-7b in SV40 immortalized hepatocytes (H2.35 cells) and found that both led to increased prolifera-
tion (Figure 3I). Collectively, our data shows that physiological let-7 levels regulate the kinetics of
adult liver regeneration by hepatocytes.
let-7g suppresses liver regeneration through insulin-PI3K-mTOR
let-7 was previously demonstrated to regulate the insulin-PI3K-mTOR pathway (Zhu et al., 2011;
Frost and Olson, 2011), which is also important in liver regeneration (Okano et al., 2003;
Chen et al., 2009; Haga et al., 2009; Espeillac et al., 2011). To avoid auto-regulatory feedback
and compensation as confounding factors, we focused on liver tissues exposed to acute let-7 gain or
loss. In regenerating livers treated with let-7g mimic (Figure 2I–K), we found significant protein sup-
pression of insulin receptor b, Igf1rb, and Irs2, previously validated let-7 targets at the top of the
insulin pathway (Figure 4A,B) (Zhu et al., 2011). In addition to insulin signaling components, the
expression of cell cycle genes (Ccnb1, Cdc34, and Cdk8) and Map4k4 were also downregulated
(Figure 4C). In mice with acute let-7b/c2 deletion by AAV-Cre (Figure 3—figure supplement 2),
there was a small increase in insulin receptor b protein levels (Figure 4D,E). Increased mTOR signal-
ing was also evident in the increased phospho-S6K/Total S6K and phospho-S6/Total S6 ratios
(Figure 5E).
To determine if mTOR signaling is functionally relevant in LKO mice, we treated mice with rapa-
mycin two hours prior to and immediately after PHx. Rapamycin abrogated differences in regenerat-
ing liver weights between control and LKO mice (Figure 4F), demonstrating that let-7b/c2 loss
promotes additional mTOR activation to enhance regeneration. Rapamycin’s allosteric inhibition of
mTOR can lead to pleiotropic and unpredictable effects due to cell-type specific and feedback
related phenomena (Thoreen et al., 2009). INK128 is a second generation mTOR inhibitor that
directly competes with ATP at the catalytic domains of mTORC1/2, leading to more complete abro-
gation of 4EBP and S6K1 (Hsieh et al., 2012). INK128, similar to rapamycin, completely abrogated
the regenerative enhancement associated with let-7b/c2 loss (Figure 4G). Analysis of p-S6K con-
firmed that mTOR is hyperactivated in LKO livers and that INK128 extinguishes the mTOR depen-
dent phosphorylation of this substrate (Figure 4H). Similar results after rapamycin and INK128
Wu et al. eLife 2015;4:e09431. DOI: 10.7554/eLife.09431 6 of 16
Research article Cell biology Developmental biology and stem cells
indicated that mTOR and its substrates play an essential role in driving increased regeneration in the
context of let-7 suppression.
Chronic high-dose let-7g causes hepatotoxicity and liver carcinogenesis
Since acute let-7g induction interferes with hepatocyte proliferation, we asked what the effects of
chronic high-dose let-7g induction might be. To answer this question, we induced let-7g using rtTA
under the control of the Rosa promoter, which drives higher expression than the LAP promoter
(Figure 5A). These mice lost significant body weight and became jaundiced (Figure 5—figure sup-
plement 1A and Figure 5). Liver function tests indicated severe liver injury (Figure 5C) and histology
showed prominent microvesicular steatosis, characterized by intra-cytoplasmic lipid droplets
(Figure 5D), a finding associated with drug-induced liver injury, acute fatty liver of pregnancy, or
Reye’s syndrome in humans. Using this system, mature let-7g was overexpressed by more than twen-
tyfold, as compared to ~eightfold induction in the LAP-let-7S21L system (Figure 5E). Liver dysfunc-
tion was not seen after low-dose let-7 overexpression in LAP-let-7S21L mice (Figure 2—figure
Figure 3. Loss of let-7b and let-7c2 is sufficient to enhance liver regeneration. (A) Schema of liver-specific let-7b and let-7c2 knockout mice (let-7b/c2
LKO). Albumin-Cre excises loxPs in the embryonic liver of let-7b/c2Fl/Fl mice. Mice without Cre serve as the controls. (B) Small RNA sequencing showing
the distribution of 10 let-7s in WT mice (n=2) (Data obtained from Xie et al. 2012). (C) Schema showing that PHx was performed on let-7b/c2Fl/Fl and let-
7b/c2 LKO mice at 56 days of age and tissues were collected 40 hr post PHx. (D) Resected liver/body weight ratios at the time of PHx, and (E) Liver to
body ratios of let-7b/c2Fl/Fl (n=11) and let-7b/c2 LKO mice (n=10) 40 hr after PHx. (F) Ki-67 staining and (G) Quantification of Ki-67-positive cells on
resected and 40 hr post-PHx liver tissues (n=3 and 3 mice; total of five 40x fields/mouse were used for quantification). (H) RT-qPCR on let-7 family
members from let-7b/c2Fl/Fl and let-7b/c2 LKO mice pre- and 40 hr post-PHx. (I) Viability of H2.35 immortalized human hepatocytes treated with either
scrambled, let-7a, or let-7b antiMiRs, measured at two and three days after transfection (n=10 each). All data in this figure are represented as mean ±
SEM. *p<0.05, **p<0.01.
DOI: 10.7554/eLife.09431.007
The following figure supplements are available for figure 3:
Figure supplement 1. Characterization of let-7b/c2 LKO mice.
DOI: 10.7554/eLife.09431.008
Figure supplement 2. Post-natal deletion of let-7b/c2 also enhances liver regeneration.
DOI: 10.7554/eLife.09431.009
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supplement 1) or after high-dose miR-26a-2 overexpression in Rosa-rtTA; TRE-miR-26a-2 mice (Fig-
ure 5—figure supplement 1B–D), suggesting a dose and let-7 microRNA specific effect.
Another possibility was that the miR-21 loop of the let-7S21L construct saturated the microRNA
biogenesis machinery, thus causing non-specific toxicity independent of the let-7 seed sequence. To
address this we again delivered a higher dose (2.0 mg/kg) of mature let-7g and control microRNA
mimics, which do not harbor loops or tails, into wild-type mice. Mice receiving let-7g mimic lost sig-
nificantly more weight (Figure 5F) and suffered hepatocyte destruction leading to increased AST/
ALT levels (Figure 5G), while control mice remained healthy. Mimic delivery achieved a twelvefold
increase of let-7g (Figure 5H). These results suggest that above certain doses let-7 is incompatible
with hepatocyte survival, and that let-7’s anti-proliferative activities would interfere with normal tis-
sue homeostasis.
Figure 4. let-7g suppresses liver regeneration through insulin-PI3K-mTOR. (A) Western blots of insulin receptor b, Igf1rb, Irs2, and b-Actin in negative
control or let-7g microRNA mimic treated liver tissues 40 hr after PHx. (B) Quantification of intensity of insulin receptor b, Igf1rb, Irs2 (Image J). (C) Cell
cycle gene expression in let-7S21L alone (n=4) and LAP-let-7S21L (n=4) livers before and 40 hr after PHx as determined by RT-qPCR. (D) Western blots
of insulin receptor b, Igf1rb, p-S6K, total S6K, b-Actin, p-S6 (Ser235/236), and total S6 in AAV-Cre treated let-7b/c2 +/+ and let-7b/c2Fl/Fl livers (n=5 and
5). (E) Quantification of intensity of insulin receptor b/b-Actin, p-S6K/total S6K, and p-S6/total S6, 40 hr after PHx (Image J). (F) Rapamycin treatment
during and after PHx in let-7b/c2Fl/Fl control and let-7b/c2 LKO mice. Shown are liver weights 40 hr post PHx. (G) INK128 treatment during and after
PHx in let-7b/c2Fl/Fl control and let-7b/c2 LKO mice. Shown are liver weights 40 hr post PHx. (H) Western blots of p-S6K, total S6K, and b-Actin in let-
7b/c2Fl/Fl control and let-7b/c2 LKO livers treated with either vehicle or INK128 at 40 hr post PHx. All data in this figure are represented as mean ± SEM.
*p<0.05, **p<0.01.
DOI: 10.7554/eLife.09431.010
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Figure 5. Chronic high-dose let-7g causes hepatotoxicity and liver carcinogenesis. (A) Schema showing that let-7S21L control and Rosa-rtTA; let-7S21L
mice were induced at 42 days of age and collected at 84 days. (B) Images showing the whole body, extremities, and livers of Rosa-rtTA (n=4) and Rosa-
let-7S21L mice (n=3) given 1 mg/mL dox between 42 and 84 days of age. (C) Liver function tests: AST (U/L), ALT (U/L), and total bilirubin (mg/L) in these
mice. (D) H&E staining of livers. (E) RT-qPCR of mature let-7s and other microRNAs in let-7g overexpressing mice (n=4 and 3). (F) Body weight 3 days
Figure 5 continued on next page
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When the Rosa-let-7S21L mice were induced chronically, approximately 50% of the mice survived
the acute liver injury seen after dox induction (Figure 5I). Over the course of 18 months, 5 of 10
(50%) of these surviving mice developed large liver tumors, whereas only 1 of 12 (7.7%) of the non-
induced mice had any tumors (Figure 5J). Chronic let-7 overexpression likely caused hepatocyte tox-
icity and selected for pre-malignant hepatocytes that eventually become cancer. Our long-term
experiments revealed the potential dangers of chronic let-7 treatment, and the consequent disrup-
tion of the balance between tissue regeneration, degeneration, and cancer risk.
Discussion
The role of let-7s in adult animal physiology is unclear in part because the redundancy of this large
microRNA family has made loss of function studies challenging. Deep redundancy of multiple highly
conserved genes raises the possibility that dose regulation is important. Despite this, overexpression
has been helpful in uncovering physiological functions of let-7 (Zhu et al., 2011; Frost and Olson,
2011; Shyh-Chang et al., 2013; Nishino et al., 2013; Madison et al., 2013). Using overexpression
tools, we have shown that let-7 suppression is a fundamental requirement for MYC-mediated liver
transformation, and that let-7 is capable of counteracting strong oncogenic drivers in vivo. However,
one negative consequence of raising the level of let-7 expression is a limitation in the ability to
regenerate after major tissue loss. More surprisingly, our knockout mouse model showed that the
loss of two out of the ten let-7 members in the liver resulted in improved liver proliferation and
regeneration. These data suggest a lack of complete redundancy between let-7 microRNA species,
but rather a precisely regulated cumulative dose that when increased or decreased, leads to signifi-
cant alterations in regenerative capacity.
The knowledge that let-7 suppresses both normal and malignant growth will have particular rele-
vance to malignancies that arise from chronically injured tissues. In these tissues, winners of the com-
petition between cancer and host cells might ultimately dictate whether organ failure or tumor
progression ensues. It has been thought that one key advantage of using microRNAs therapeutically
is that they are already expressed at high levels in normal tissues, thus making increased dosing
likely to be safe and tolerable. Surprisingly, we showed that chronic let-7 overexpression caused
hepatotoxicity, disrupted tissue homeostasis, ultimately leading to carcinogenesis. This is likely due
to the high levels of overexpression achieved in the Rosa-rtTA transgenic system, as opposed to the
lower dose in the LAP-tTA system. These high doses are likely to be toxic to hepatocytes, a phenom-
ena compounded by the fact that excess let-7 impairs proliferation in surviving cells that might serve
to replenish lost tissues. Eventually, certain clones must epigenetically or genetically evolve to evade
let-7 growth inhibition in order to transform.
It is also interesting that let-7 overexpression led to dramatically different outcomes in distinct
cancer contexts. While dose is most likely the critical variable between the Rosa-rtTA and LAP-tTA
systems, Rosa-rtTA does induce expression in cells other than hepatocytes and bile duct epithelia,
leaving the possibility that non-cell autonomous influences of let-7 overexpression play a role in liver
injury and cancer development. A more interesting possibility would be if distinct genetic subtypes
of cancer respond differently to let-7 overexpression. Since let-7 has been conceptualized as a gen-
eral tumor suppressor, it is surprising that it can cause opposing phenotypes in distinct cancer mod-
els. MYC liver cancers show a dramatic suppression of let-7, rendering it especially sensitive to let-7
replacement. Tumors or tissues with more normal levels of let-7 might not respond to increases in
Figure 5 continued
after injection of 2.0 mg/kg negative control or let-7g microRNA mimics packaged in C12-200 LNPs relative to pre-injection weight (n=5 and 4).
(G) Liver function tests: AST (U/L) and ALT (U/L) in WT C57Bl/6 mice before and 3 days after mimic injection (n=5 and 4). (H) Mature let-7 levels in wild-
type C57Bl/6 mice treated with mimics as determined by RT-qPCR (n=5 and 4). (I) Kaplan-Meier curve for Rosa-let-7S21L induced with 1.0 g/L dox at 6
weeks old (n=15 and 17). (J) Gross images of the liver of Rosa-let-7S21L mice induced for 18 months. All data in this figure are represented as mean ±
SEM. *p<0.05, **p<0.01.
DOI: 10.7554/eLife.09431.011
The following figure supplement is available for figure 5:
Figure supplement 1. Data associated with Figure 5.
DOI: 10.7554/eLife.09431.012
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let-7. Alternatively, the growth of other cancer models may not depend on the overproduction of
let-7 target genes/proteins. let-7 overexpression in these contexts would probably not elicit growth
suppression, but may instead exacerbate tissue injury. It would be interesting to evaluate the effects
of let-7 overexpression in hepatocellular carcinomas caused by different driver mutations. Together,
our data suggest that let-7 therapy directed at hepatocellular carcinomas could be risky, given that
most of these cancers occur in severely compromised, cirrhotic livers (Yang et al., 2011).
We speculate that the total dose of let-7 is evolutionarily determined via regulation of the expres-
sion levels of individual let-7 members, and is postnatally maintained at a level that can suppress
cancer, but which also allows for adequate levels of mammalian regenerative capacity. Clearly, let-7
levels are not static throughout life, since let-7 levels are dynamic after environmental perturbations.
However, when baseline let-7 levels are altered permanently by genetic means, compromises in
tumor suppression or tissue regeneration were revealed. Our study underscores the importance of




All mice were handled in accordance with the guidelines of the Institutional Animal Care and Use
Committee at UTSW. MYC tumor models and the LAP-let-7S21L inducible mice were carried on a
1:1 FVB/C57Bl/6 strain background. Please see (Nishino et al., 2013) for more details about the let-
7b/c2 floxed mice, which are on a C57Bl/6 background. The chronically injured let-7 inducible mice
were on a mixed B6/129 background. All experiments were done in an age and sex controlled fash-
ion unless otherwise noted in the figure legends.
Partial hepatectomy
Two-thirds of the liver was surgically excised as previously described (Mitchell and Willenbring,
2008).
RNA extraction and RT-qPCR
Total RNA was isolated using Trizol reagent (Invitrogen). For RT-qPCR of mRNAs, cDNA synthesis
was performed with 1 ug of total RNA using miScript II Reverse Transcription Kit (Cat. #218161, Qia-
gen). Gene expression levels were measured using the DDCt method as described previously
(Zhu et al., 2010).
Western blot assay
Mouse liver tissues were ground with a pestle and lysed in T-PER Tissue Protein Extraction Reagent
(Thermo Scientific Pierce). Western blots were performed in the standard fashion. The following anti-
bodies were used: Anti-Insulin receptor b (Cell Signaling #3025), Anti-Igf1rb (Cell Signaling #9750),
Anti-Irs2 (Cell Signaling #3089), Anti-total S6K (Cell Signaling #9202), Anti-p-S6K (Cell Signaling
#9205), Anti-total S6 (Cell Signaling #2217), Anti-p-S6 Ser235/236 (Cell Signaling #2211), Anti-mouse
b-Actin (Cell Signaling #4970), Anti-rabbit IgG, HRP-linked Antibody (Cell Signaling #7074) and Anti-
mouse IgG, HRP-linked Antibody (Cell Signaling #7076).
Histology and immunohistochemistry
Tissue samples were fixed in 10% neutral buffered formalin or 4% paraformaldehyde (PFA) and
embedded in paraffin. In some cases, frozen sections were made. Immunohistochemistry was per-
formed as previously described (Zhu et al., 2010). Primary antibodies used: Ki-67 (Abcam
#ab15580). Detection was performed with the Elite ABC Kit and DAB Substrate (Vector Laborato-
ries), followed by Hematoxylin Solution counterstaining (Sigma).
Liver function tests
Blood samples (~50 ul) were taken retro-orbitally in heparinized tubes. Liver function tests were ana-
lyzed by the UTSW Molecular Genetics core.
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Viral Cre excision
100 mL of AAV8.TBG.PI.Cre.rBG (University of Pennsylvania Vector Core) was retro-orbitally injected
at a titer of 5 x 1010 genomic particles to mediate 90%-–100% Cre excision.
Cell culture and in vitro antiMiR experiments
The H2.35 cell line was directly obtained from ATCC and has been cultured for less than 6 months.
The cells were authenticated by ATCC using Short Tandem Repeat (STR) DNA profiling. Cells were
cultured in DMEM with 4% (vol/vol) FBS, 1x Pen/Strep (Thermo Scientific) and 200 nM Dexametha-
sone (Sigma). Cells were transfected with control (Life Technologies Cat. AM17010), let-7a (Life
Technologies Cat. #4464084-Assay ID MH10050), or let-7g (Life Technologies Cat. #4464084-Assay
ID MH11050) miRVana antiMiRs. AntiMiRs were packaged by RNAiMAX (Invitrogen) and transfected
into H2.35 cells cultured in 96-well plates at a concentration of 50 nM. The number of viable cells in
each well was measured at 2 and 3 days after transfection using CellTiter-Glo Luminescent Cell Via-
bility Assay (Promega Cat. #G7570).
In vivo microRNA mimic experiments
For in vivo experiments, formulated C12-200 lipidoid nanoparticles (LNPs) were used to package
either Control (Life Technologies Cat. #4464061) or let-7g (Life Technologies Cat. 364 #4464070-
Assay ID MC11758) miRVana mimic at either 0.5 or 2 mg/kg and delivered intravenously through the
tail vein. LNPs were formulated following the previously reported component ratios (Love et al.,
2010) with the aid of a microfluidic rapid mixing instrument (Precision Nanosystems NanoAssemblr)
and purified by dialysis in sterile PBS before injection.
In vivo drug treatments
Rapamycin (LC Biochem) was dissolved in 25% ethanol/PBS and then injected at 1.5 mg/kg 2 hr prior
to and 20 hr after PHx. INK128 (LC Biochem) was formulated in 5% polyvinylpropyline, 15% NMP,
80% water and administered by oral gavage at 1 mg/kg 2 hr prior to and 20 hr after PHx.
MicroRNA sequencing
Female CD1 mice were treated with 3 mg/kg TCPOBOP in DMSO-corn oil by gavage (Tian et al.,
2011), sacrificed at 3, 6, 9, 12, and 18 hr after treatment, and compared to untreated controls. Repli-
cate libraries were made from two individual mice for each condition. RNA was purified with the Qia-
gen miRNeasy Mini kit. Small RNA libraries were constructed using an Illumina Truseq Small RNA
Sample Prep Kit. 12 indexed libraries were multiplexed in a single flow cell lane and received 50
base single-end sequencing on an Illumina HiSeq 2500 sequencer. Sequence reads were aligned to
mm9 using Tophat and quantified with Cufflinks by the FPKM method (Trapnell et al., 2012). Data
for each experimental condition represent the average values from two libraries.
Statistical analysis
The data in most figure panels reflect multiple experiments performed on different days using mice
derived from different litters. Variation is always indicated using standard error presented as mean ±
SEM. Two-tailed Student’s t-tests (two-sample equal variance) were used to test the significance of
differences between two groups. Statistical significance is displayed as p<0.05 (*) or p<0.01 (**)
unless specified otherwise. In all experiments, no mice were excluded form analysis after the experi-
ment was initiated. Image analysis for the quantification of cell proliferation, cell death, and fibrosis
were blinded.
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